| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5898950 | Diabetes Research and Clinical Practice | 2016 | 7 Pages |
Abstract
By normalizing CET in T2D, probucol likely reduces the formation of atherogenic lipoproteins. This effect on CET is achieved through qualitative alterations in CETP's lipoprotein substrates and not through changes in CETP or HDL. Since probucol also has potent anti-oxidative and anti-inflammatory properties, it may have a new role to play in lipoprotein remodeling that reduce cardiovascular risk in T2D.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
John D. Bagdade, James T. Lane, P.V. Subbaiah,